Roche also halted a phase 3 trial of Tecentriq with cabozantinib ... The recombinant human pentraxin-2 (PTX-2) drug is no longer listed in Roche’s R&D pipeline, and was previously in development ...

The transaction includes an upfront fee of $150 million and will give BMS a worldwide licence for PRM-151, a recombinant form of human pentraxin-2 ... of galectin-3. Since then the US drugmaker ...

I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular ...

In this research group, the research areas of global surgery and reconstructive plastic surgery meet. The research is to a large extent focused on the development and improvement of surgical health ...